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Only a decade ago, it was believed that a genetic diagnosis of intellectual disability and 
autism offered little in the way of hope for a medical treatment to lessen the burden on 
the affected individuals and their families. However, recent research aimed at 
understanding the cellular and molecular mechanisms that underlie the pathogenesis of 
ASD has ushered in a new era of targeted treatment strategies. Studies in fragile X 
syndrome (FXS) have been at the forefront of this revolution, and they are forging a path 
that could define future approaches to the treatment of ASD. 
FXS is the leading identified genetic cause of autism. Because it is a defined genetic 
disorder that can be effectively modeled in animals, the study of FXS has great potential 
to yield information about the pathophysiology of ASD. FXS is caused by a silencing of 
the FMR1 gene and the loss of fragile X mental retardation protein (FMRP), a repressor 
of mRNA translation. Early studies suggested that synaptic protein synthesis is stimulated 
by activation of group 1 (Gp1) metabotropic glutamate receptors (comprising mGluR1 
and mGluR5) and that one functional consequence of this protein synthesis is the long-
term depression (LTD) of synaptic strength (reviewed in in Bhakar et al. [1]). The 
subsequent discovery that LTD is elevated in the mouse model of FXS (Fmr1-/y) led to 
the proposal that multiple symptoms of the disease might be accounted for by heightened 
responsiveness to Gp1 mGluR activation. This mGluR theory of fragile X predicted that 
the antagonism of Gp1 mGluRs should correct pathologic changes in FXS (2). In the 
decade that elapsed since it was first proposed, numerous studies in a range of animal 
models have validated this theory. The animal data show that many aspects of FXS can 
be accounted for by altered Gp1 mGluR signaling at synapses. This insight is the basis 
for multiple clinical trials that are now underway in FXS (for extensive reviews see 
Bhakar et al. [1] and Krueger and Bear [3]). 
The first clinical test of the mGluR theory was a small, open-label trial using fenobam, a 
Gp1 mGluR antagonist that is highly selective for mGluR5. The results of this small trial 
showed beneficial effects on a subset of the adult FXS patients tested; however, it is 
important to note that no placebo control group was included in this trial, nor was it 
performed in an experimenter blind fashion (4). Since this initial study, multiple large-
scale placebo-controlled trials have been initiated with selective mGluR5 negative 
allosteric modulators— namely, STX107 (Seaside Therapeutics, Cambridge, 
Massachusetts), RG7090 (Hoffman-LaRoche, Basel, Switzerland), and AFQ056 
(Novartis, Basel, Switzerland). Although the results of most of these trials have yet to be 
revealed, in post hoc analysis of Phase II data AFQ056 was reported to show an 
improvement on multiple behavioral tests in adult patients with a fully methylated 
(silenced) FMR1 gene. 
In tandem with drugs that directly interfere with mGluR5, other drugs that may indirectly 
target Gp1 mGluR signaling are also being tested in clinical trials. One strategy for 
reducing mGluR activation is to suppress glutamate release at excitatory synapses, and 
this can be achieved by the activation of GABAB receptors. Early studies based on this 
idea showed that the GABA receptor agonist  baclofen could drastically reduce the 
incidence of audiogenic seizures in Fmr1-/y mice (reviewed in Krueger and Bear [3]).  
Figure 1. Inhibition of metabotropic glutamate receptors (mGluR) signaling in fragile X syndrome (FXS). 
Schematic shows how mGluR signaling is targeted to treat FXS. Fragile X mental retardation protein 
inhibits messenger (m)RNA translation downstream of constitutive activation of mGluR5, resulting in 
excessive protein synthesis and exaggerated mGluR long-term depression (LTD). Fenobam, STX107, 
RG7090, and AFQ056 negatively regulate mGluR5 at allosteric sites. Arbaclofen activates gamma-
aminobutyric acid B (GABAB) receptors, thereby inhibiting vesicular glutamate release. Lithium targets 
both phospholipase C (PLC) and glycogen synthase kinase 3 (GSK3), two pathways that are activated 
downstream of Gp1 mGluRs. LP-211 enhances 5-HT7 receptor activation, stimulating the production of 
cAMP. This may negatively regulate extracellular signal-regulated kinase (ERK)1/2 signaling by targeting 
Raf1. AC, ; AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; AMPAR, AMPA 
receptor; cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol; DHPG, 3,5-
Dihydroxyphenylglycine; FMRP, fragile X mental retardation protein; GSK3, glycogen synthase kinase 3; 
IP3, inositol triphosphate; MEK, MAP kinase kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, 
protein kinase C; PLC, phospholipase C; Raf, Raf serine/threonine-protein kinase; Ras, RAt sarcoma 
protein. 
More recently, a study using the R-isomer of baclofen (arbaclofen or STX209, Seaside 
Therapeutics) finds that multiple phenotypes in Fmr1-/y mice are corrected, including 
abnormal dendritic spine density, excessive protein synthesis, exaggerated alpha-amino-
3hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor trafficking, and 
audiogenic seizures (Henderson et al. [5]). Importantly, recent results from a double-
blind placebo-controlled study of 63 patients with FXS revealed arbaclofen treatment 
results in significant improvement in clinical presentation (Berry-Kravis et al. [6]). 
Arbaclofen is currently in Phase III clinical trials for the treatment of FXS. 
Other therapeutic strategies have targeted the signaling pathways downstream of Gp1 
mGluRs. The phospholipase C (PLC) and glycogen synthase kinase 3 (GSK3) signaling 
pathways are both stimulated by Gp1 mGluR activation, and the latter is hyperactive in 
theFmr1-/y.Preclinical studies show that lithium ,a drug that inhibits PLC and GSK3, can 
correct multiple phenotypes in the Fmr1-/y, and an open-label clinical trial showed 
behavioral improvements in FXS patients (for review, see Krueger and Bear [3]). 
Another important pathway activated by Gp1 mGluRs is the extracellular signalregulated 
kinase 1/2 (ERK1/2) signaling cascade, which is activated by the G-protein Ras, which 
leads to the sequential phosphorylation of Raf1 and MEK1/2. The Fmr1-/y mouse is 
hypersensitive to signaling through this pathway, and inhibition of ERK1/2 corrects 
multiple pathologic phenotypes in the Fmr1-/y, including excessive protein synthesis, 
hippocampal epileptiform activity, and susceptibility to AGS (for review, see Bhakar et 
al. [1]). Investigation into clinically viable strategies for targeting this pathway is 
ongoing. 
In the current issue of Biological Psychiatry, Costa et al. (7) propose the 5-HT7 serotonin 
receptor as a novel target for the treatment of FXS. They show that activation of 5-HT7 
inhibits mGluR-LTD induced by 3,5-Dihydroxyphenylglycine (DHPG), a Gp1 mGluR 
agonist. This effect is observed in both wild-type and Fmr1-/y hippocampus. Application 
of either serotonin (5-HT) or 8-Hydroxy-2dipropylaminotetralin hydrobromide (8-OH 
DPAT), a 5-HT7 and 5-HT1A receptor agonist, suppresses mGluR-LTD when applied 
within 15 min of induction. A specific 5-HT7 agonist, LP-211, also blocks the induction 
of mGluR-LTD. The suppressive effect of 8-OH DPAT on LTD is blocked by application 
of a specific antagonist to 5-HT7, but not 5-HT1A, receptors. Together, these results show 
that activation of 5-HT7 inhibits the induction of mGluR-LTD, suggesting two hypotheses 
of particular interest: 1) that the Gp1 mGluR and 5-HT pathways functionally interact; 
and 2) that 5-HT7 receptor agonists can correct pathologic changes in FXS. 
5-HT modulates the release of several neurotransmitters, including glutamate and 
gamma-aminobutyric acid, and the expression of 5-HT receptors is widespread. 
Accumulating evidence suggests that 5-HT7, the most recently characterized 5-HT 
receptor, plays a role in enhancing memory formation. Multiple behavioral studies have 
shown that antagonism of 5-HT7 receptors impairs long-term memory, and studies using 
5-HT7 agonists show a beneficial effect on instrumental and associative memory 
formation (reviewed in Roberts and Hedlund [8]). Consistent with these findings, studies 
performed on 5-HT7 knockout mice show a deficit in contextual fear conditioning, a 
hippocampal learning task, as well as deficient LTP in hippocampal CA1 (9). However, 
the mechanism through which 5-HT7 activation enhances memory formation is largely 
unknown. It is interesting to speculate that the suppressive action of 5-HT7 activation on 
mGluR-LTD observed by Costa et al. is relevant to its positive impact on hippocampal 
learning. 
Given the antagonistic effect of 5-HT7 activation on mGluR-LTD, a pertinent question is 
whether other functional consequences of mGluR activation could be similarly dampened 
by 5-HT7 agonists, particularly in the context of FXS. It will be important to assess in 
future studies if 5-HT7 compounds can ameliorate the same broad array of Fmr1- /y 
phenotypes as respond to inhibition of mGluR5. In the meantime, it is interesting to 
consider the mechanism through which 5-HT7 activation might suppress mGluR-LTD. 
Costa et al. find that 8-OH DPAT did not affect a presynaptically expressed form of 
mGluR-LTD, thus it is likely that 5-HT7 activation blocks LTD via a postsynaptic 
mechanism. The inhibition of DHPG-induced AMPA receptor (AMPAR) endocytosis by 
8-OH DPAT, in both acute slices and dissociated hippocampal cultures, also suggests that 
5-HT7 acts postsynaptically. The authors speculate that the inhibition of LTD by 5-HT7 
activation could be due to a change in the phosphorylation and trafficking of specific 
AMPAR subunits. Another enticing possibility is that 5-HT7 activation negatively 
modulates a shared signaling pathway downstream of Gp1 mGluRs (Figure 1). 5-HT7 is a 
G protein coupled receptor that activates Gs, which stimulates adenylate cyclase and 
increases the production of cyclic adenosine monophosphate (cAMP) (8). Studies from 
several cell types have found that cAMP can inhibit the activation of Raf1 and 
subsequently downregulate ERK1/2 signaling (10). Thus, it is possible that activation of 
5-HT7 inhibits mGluR-LTD by dampening the ERK1/2 pathway. In this context, it is 
interesting to note that a robust finding in both the Fmr1-/y mouse and in cells isolated 
from FXS patients is an impairment in cAMP production (11). 
The study by Costa et al. (7) joins a growing body of research linking the negative 
regulation of Gp1 mGluRs to a correction of pathologic changes in FXS. Several 
compounds that target mGluRs and associated signaling pathways have shown promise in 
the clinic, and additional treatment strategies based on the mGluR theory continue to be 
developed (Figure 1). This has relevance not only for FXS but for the treatment of the 
greater ASD population. The notion that a neurodevelopmental disorder can be treated 
with pharmacologic intervention has heretofore been seen as naive. However, evidence to 
the contrary is accumulating, and it is now becoming accepted that treatment can be 
beneficial even when administered later in development (12). The recent studies in FXS 
thus represent a paradigm shift in our thinking about the treatment of neurodevelopmental 
disorders. The door has been opened for a new wave of targeted treatment strategies for 
FXS and related ASD. 
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